2023 World Conference on Lung Cancer (Posters)-EP13.01. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer with an Emphasis on Oligo-Progressive Disease

EP13.01. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer with an Emphasis on Oligo-Progressive Disease - PDF(Slides)

Back to course

Pdf Summary

This study aimed to present the clinical experience of using consolidative thoracic radiotherapy for extensive-stage small cell lung cancer (SCLC), with a focus on patients with oligo-progressive disease. The researchers conducted a retrospective review of the medical records of 36 SCLC patients treated between June 2017 and December 2021. Out of these, 26 patients had limited-stage SCLC and were treated with definitive concurrent chemoradiotherapy (CCRT), while 10 patients had extensive-stage SCLC and showed partial response or oligo-progressive disease after prior systemic therapy and were subsequently treated with consolidative radiotherapy. The median follow-up time was 20 months. The one-year overall survival (OS) and disease-free survival (DFS) rates were 87.3% and 56.0%, respectively, for patients treated with definitive aim, and 88.9% and 60.0%, respectively, for patients treated with consolidative aim. The study suggests that in the current era of targeted and immunotherapy use, if the disease is adequately managed and localized by systemic therapy, local consolidative radiotherapy can maximize therapeutic effects with minimal harm. Distant metastasis was found to be the most common type of recurrence in both the definitive and consolidative therapy groups, while no cases of in-field locoregional recurrences were observed. The study was supported by the National Research Foundation of Korea and Korea University Guro Hospital.

Asset Subtitle

Hakyoung Kim

Meta Tag

Speaker Hakyoung Kim

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

consolidative thoracic radiotherapy

extensive-stage small cell lung cancer

oligo-progressive disease

retrospective review

limited-stage SCLC

definitive concurrent chemoradiotherapy

consolidative radiotherapy

overall survival

disease-free survival

distant metastasis